NIT
AIMT

NumerixS Investment Technologies’s Aimmune Therapeutics AIMT Stock Holding History

NumerixS Investment Technologies’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,698
Closed -$212K – 1389
2020
Q1 		$212K Buy
+14,698
New +$376K 0.11% 232
2019
Q4 		– Sell
-200
Closed -$4K – 1311
2019
Q3 		$4K Buy
+200
New +$4.08K ﹤0.01% 976
2018
Q4 		– Sell
-400
Closed -$11K – 1508
2018
Q3 		$11K Buy
+400
New +$11.3K ﹤0.01% 1129

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

NumerixS Investment Technologies's AIMT Position: Q2 2020 in Review

NumerixS Investment Technologies sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 14,698 shares — an estimated $212K sold.

NumerixS Investment Technologies first reported a position in AIMT in Q3 2018 and held it in 3 quarters. The position peaked at $212K in Q1 2020. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • NumerixS Investment Technologies reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 14,698 Aimmune Therapeutics shares in Q2 2020, an estimated $212K.
  • NumerixS Investment Technologies first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 3 quarters.
  • NumerixS Investment Technologies's Aimmune Therapeutics position peaked at $212K in Q1 2020.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on NumerixS Investment Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.